Group 1 - Oscar Health, Inc. (NYSE:OSCR) experienced a significant decline of 17.6% in its stock price, attributed to concerns over healthcare subsidies [1] - The stock had previously surged by 7.9% in October following the announcement of a new insurance product targeting perimenopause and menopause [1] - Year-to-date, Oscar Health's shares are up by 7.8%, benefiting from reaffirmed full-year growth guidance in September, which resulted in a 16.6% week-over-week gain [2] Group 2 - Jim Cramer emphasized the necessity of healthcare subsidies for Oscar Health, indicating that the company is not un-investable despite recent volatility [1] - The discussion highlighted the broader market impact, with other healthcare stocks like DaVita and Molina also affecting market performance [1]